Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355766 | 1.00 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2HRH4 | |
| SCHEMBL8936625 | 0.85 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2HRH4 | |
| SCHEMBL8936584 | 0.85 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2HRH4 | |
| SCHEMBL353648 | 0.85 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2HRH4 | |
| SCHEMBL13866341 | 0.85 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2HRH4 | |
| SCHEMBL25331527 | 0.85 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2HRH4 | |
| SCHEMBL14072251 | 0.84 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2PSEN1 | |
| SCHEMBL7249511 | 0.82 | SMYD2 (0.41) | SMYD2CYP3A4HTTSMN1; SMN2PSEN1 | |
| SCHEMBL10237481 | 0.82 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2PSEN1 | |
| SCHEMBL354303 | 0.82 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | SMYD2 238/4885CYP3A4 1232/4885HTT 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.